Australian shares rebounded at Tuesday's close as market sentiment improved over US President Donald Trump's comments on the conflict in the Middle East.

The S&P/ASX 200 Index regained 1.09%, or 93.60 points, to close at 8,692.60.

Oil prices fell below the $100 per barrel mark, and it was $94.37 per barrel at close. US President Donald Trump told CBS the military operation in the Middle East was "very complete, pretty much" and "very far" ahead of its initial four-to-five-week schedule.

On the domestic front, seasonally adjusted data showed that the total number of dwellings approved in Australia fell 7.2% to 14,564 in January from 15,693 in the previous month, according to final figures from the Australian Bureau of Statistics.

The total value of residential dwellings in Australia rose 3.2% in the December 2025 quarter, settling at AU$12.307 trillion, figures from the Australian Bureau of Statistics showed.

In company news, Telix Pharmaceuticals (ASX:TLX) said the first part of its ProstACT Global phase three study achieved its primary objectives, confirming the safety profile, biodistribution, and dosimetry of the drug candidate TLX591-Tx, or lutetium-177 rosopatamab tetraxetan in combination with one of three standard of care therapies, abiraterone, enzalutamide, or docetaxel. Shares of the firm jumped 8% on market close.

CSL (ASX:CSL) disclosed the $1.5 billion expansion of its Illinois plasma therapy manufacturing facility, and the expansion, set to be operational by 2031, will feature the company's Horizon 2 technology. Its shares closed up 2%.

Lastly, Orica (ASX:ORI) said its earnings before interest and taxes (EBIT) is expected to be slightly higher in the first half of the year than the half-year in the prior corresponding period. It expects its cost savings program to deliver at least AU$100 million of annualized cost savings, realized across the next three years. Its shares were down 3% on market close.